/
IRWD
$4.30+$0.17 (+4.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$679.9M
165M shares
52-week range
$0.67 – $5.78
71% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.36%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $346.6M | $428.4M | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | $296.2M |
| Cost of revenue | $32.8M | $135.4M | $3.1M | $70.4M | $1.4M | $6.1M | $7.6M | $0 |
| Gross profit | $313.9M | $293.0M | $386.4M | $343.3M | $409.2M | $436.6M | $343.9M | $296.2M |
| Gross margin | 90.6% | 68.4% | 99.2% | 83.0% | 99.7% | 98.6% | 97.9% | 100.0% |
| R&D | $166.5M | $122.2M | $88.1M | $70.4M | $44.3M | $116.1M | $111.4M | $95.1M |
| Operating income | −$238.9M | $120.1M | $142.9M | $232.3M | $250.3M | −$945.4M | $93.1M | $118.8M |
| EBITDA | −$144.5M | $128.6M | $141.9M | $233.7M | $261.4M | $197.4M | $97.7M | $104.7M |
| Net income | −$282.4M | $21.5M | $106.2M | $528.4M | $175.1M | −$1.00B | $880.0K | $24.0M |
| Net margin | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
| EPS (diluted) | -1.85 | -0.10 | 0.66 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $462M | $1.18 | $1.16–$1.19 | 1 |
| 2027 | $481M | $1.24 | $1.22–$1.25 | 2 |
| 2028 | $493M | $1.41 | $1.39–$1.43 | 1 |
| 2029 | $249M | $0.56 | $0.55–$0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.52
Price
$4.30
Implied upside
+52%
Peer comparison
Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
www.ironwoodpharma.com- Employees
- 100
- IPO / List date
- Feb 3, 2010
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds IRWD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 8,061,073 | $28.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IRWD yet.
